ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
ZyVersa Therapeutics Inc

ZyVersa Therapeutics Inc (ZVSA)

1,0601
0,04
(3,93%)
Fermé 10 Décembre 10:00PM
1,0601
0,00
( 0,00% )
Avant marché: 10:10AM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
1,0601
Prix Achat
1,00
Prix Vente
1,10
Volume échangé
1
0,00 Fourchette du Jour 0,00
0,9801 Plage de 52 semaines 25,00
Cap du marché
Clôture Veille
1,0601
Ouverture
-
Dernière Transaction
1
@
1.1
Dernière heure de transaction
10:03:04
Volume financier
-
VWAP
-
Volume moyen (3 m)
1 317 729
Actions en circulation
2 344 191
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,50
Bénéfice par action (BPA)
-45,32
Chiffre d'affairess
-
Bénéfice net
-106,25M

À propos de ZyVersa Therapeutics Inc

ZyVersa Therapeutics Inc is a clinical stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop and commercialize first-in-class prescription drugs. The company's focus is on restoring health and improving quality of life for patients with high unmet medi... ZyVersa Therapeutics Inc is a clinical stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop and commercialize first-in-class prescription drugs. The company's focus is on restoring health and improving quality of life for patients with high unmet medical needs, with emphasis on inflammatory and renal diseases. Show more

Secteur
Pharmaceutical Preparations
Industrie
Blank Checks
Site Web
Siège social
Wilmington, Delaware, USA
Fondé
2022
ZyVersa Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ZVSA. Le dernier cours de clôture d'ZyVersa Therapeutics était de US$1,06. Au cours de la dernière année, les actions de ZyVersa Therapeutics ont été négociées dans une fourchette de prix de US$ 0,9801 à US$ 25,00.

ZyVersa Therapeutics compte actuellement 2 344 191 actions en circulation. La capitalisation boursière d'ZyVersa Therapeutics est de US$2,49 million. ZyVersa Therapeutics a un ratio cours/bénéfice (ratio PE) de -0.50.

ZVSA Dernières nouvelles

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.Cardiac complications following a stroke are a leading...

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor...

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic &...

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta...

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders.With...

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseasesThe newly published data show that obesity...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.04013.931372549021.021.150.9801732231.03164497CS
4-0.1899-15.1921.251.350.98012703201.14154527CS
12-1.1699-52.46188340812.233.370.980113177292.37506441CS
26-3.3699-76.06997742664.436.30.98016854722.5622412CS
52-7.6389-87.81354178648.699250.980111492517.25284573CS
156-4898.9399-99.978365306149005232.50.9801201466980.12786157CS
260-4898.9399-99.978365306149005232.50.9801201466980.12786157CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CMRXChimerix Inc
US$ 2,01
(132,37%)
1,32M
CPIXCumberland Pharmaceutical Inc
US$ 2,115
(70,56%)
4,33M
GELSGelteq Ltd
US$ 5,24
(47,19%)
591,3k
VRARGlimpse Group Inc
US$ 1,19
(41,67%)
657,36k
PCSAProcessa Pharmaceuticals Inc
US$ 1,66
(32,80%)
1,02M
MRMMEDIROM Healthcare Technologies Inc
US$ 1,765
(-36,96%)
57,54k
HUIZHuize Holding Ltd
US$ 4,96
(-18,15%)
2,88k
MNTSMomentus Inc
US$ 0,48
(-14,76%)
4,78k
VTVTvTv Therapeutics Inc
US$ 15,00
(-14,58%)
100
DUOFangDD Network Group Ltd
US$ 0,756
(-14,06%)
597,2k
CPIXCumberland Pharmaceutical Inc
US$ 2,115
(70,56%)
4,33M
CMRXChimerix Inc
US$ 2,01
(132,37%)
1,32M
PCSAProcessa Pharmaceuticals Inc
US$ 1,66
(32,80%)
1,02M
RGTIRigetti Computing Inc
US$ 4,62
(3,36%)
858,9k
LDTCLeddarTech Holdings Inc
US$ 1,38
(-7,38%)
837,91k
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock